Mesoblast's (MESO) Sell (E+) Rating Reaffirmed at Weiss Ratings

Key Points

• Mesoblast's stock has received a "sell (e+)" rating from Weiss Ratings, indicating ongoing concerns about its performance.
• Despite the sell rating, Mesoblast's stock recently rose by 9.2%, bringing its price to $19.75.
• Research on Mesoblast shows a mixed outlook, with ratings ranging from "Strong Buy" to "Sell," and a consensus target price of $24.00.

Mesoblast (NASDAQ:MESO - Get Free Report)'s stock had its "sell (e+)" rating restated by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group upgraded shares of Mesoblast to a "strong-buy" rating in a research note on Tuesday, August 5th. Jefferies Financial Group cut shares of Mesoblast from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

Mesoblast Stock Up 9.2%

Shares of MESO opened at $19.75 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.99 and a quick ratio of 1.77. Mesoblast has a 52 week low of $7.09 and a 52 week high of $22.00. The stock has a 50 day moving average price of $15.63 and a two-hundred day moving average price of $13.08.

Hedge Funds Weigh In On Mesoblast

A number of hedge funds have recently modified their holdings of the company. Advisors Preferred LLC increased its stake in shares of Mesoblast by 224.9% during the first quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock valued at $54,000 after buying an additional 3,169 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Mesoblast during the 2nd quarter valued at about $86,000. China Universal Asset Management Co. Ltd. increased its position in shares of Mesoblast by 33.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,124 shares of the company's stock valued at $99,000 after buying an additional 2,302 shares during the period. Ballentine Partners LLC purchased a new stake in Mesoblast in the second quarter worth about $124,000. Finally, R Squared Ltd purchased a new position in shares of Mesoblast during the 2nd quarter worth approximately $126,000. Hedge funds and other institutional investors own 1.43% of the company's stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.